Document Detail

Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
MedLine Citation:
PMID:  22750997     Owner:  NLM     Status:  MEDLINE    
Palifermin, a recombinant human keratinocyte growth factor, is commonly given to prevent mucositis following autologous transplantation. In the allogeneic hematopoietic stem cell transplant (allo-HSCT) setting, safety and efficacy data are limited. We conducted a retrospective study in 251 patients undergoing allo-HSCT, 154 of whom received peritransplant palifermin. In all patients, palifermin significantly decreased the mean number of days of total parenteral nutrition (TPN, 13 vs 16 days, P=0.006) and patient-controlled analgesia (PCA, 6 vs 10 days, P=0.023), as well as the length of initial hospital stay (LOS, 32 vs 37 days, P=0.014). However, the effect of palifermin was only significant in patients who received a TBI- but not BU-based chemotherapy conditioning regimen. In TBI recipients, palifermin decreased the mean number of days of TPN (13 vs 17 days, P<0.001) and PCA (7 vs 12 days, P=0.033), and the length of stay (32 vs 38 days, P=0.001). Palifermin did not affect GVHD, graft failure or relapse. Therefore, in the largest analysis with this patient population to date, we demonstrate that palifermin is safe in allo-HSCT patients, decreases TPN and PCA use and decreases LOS following TBI-based but not chemotherapy-based allo-HSCT.
J D Goldberg; J Zheng; H Castro-Malaspina; A A Jakubowski; G Heller; M R M van den Brink; M-A Perales
Related Documents :
11443587 - Technical challenges of hepatic venous outflow reconstruction in right lobe adult livin...
16421487 - Fatal pneumonia caused by panton-valentine leucocidine-positive methicillin-resistant s...
14961997 - Impact of adult living donor liver transplantation on waiting time survival in candidat...
17245187 - Outcomes of adult-to-adult living donor liver transplantation: a single institution's e...
10359337 - Rescue effects of ipe transplants in rcs rats: short-term results.
16182767 - Transjugular intrahepatic portosystemic shunt in adult liver recipient with delayed gra...
Publication Detail:
Type:  Clinical Trial, Phase II; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-07-02
Journal Detail:
Title:  Bone marrow transplantation     Volume:  48     ISSN:  1476-5365     ISO Abbreviation:  Bone Marrow Transplant.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-09     Completed Date:  2013-06-24     Revised Date:  2014-06-15    
Medline Journal Info:
Nlm Unique ID:  8702459     Medline TA:  Bone Marrow Transplant     Country:  England    
Other Details:
Languages:  eng     Pagination:  99-104     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects,  pharmacology
Cohort Studies
Fibroblast Growth Factor 7 / adverse effects,  genetics,  therapeutic use*
Follow-Up Studies
Gastrointestinal Tract / drug effects*,  physiopathology,  radiation effects
Hematopoietic Stem Cell Transplantation / adverse effects*
Middle Aged
Mucositis / epidemiology,  etiology,  physiopathology,  prevention & control*
New York City / epidemiology
Protective Agents / adverse effects,  therapeutic use*
Recombinant Proteins / therapeutic use
Retrospective Studies
Severity of Illness Index
Survival Analysis
Transplantation Conditioning / adverse effects*,  methods
Transplantation, Homologous
Whole-Body Irradiation / adverse effects*
Young Adult
Grant Support
Reg. No./Substance:
0/Antineoplastic Agents; 0/FGF7 protein, human; 0/Protective Agents; 0/Recombinant Proteins; 126469-10-1/Fibroblast Growth Factor 7

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hyperbilirubinemia in the early phase after allogeneic HSCT: prognostic significance of the alkaline...
Next Document:  Foscarnet against human herpesvirus (HHV)-6 reactivation after allo-SCT: breakthrough HHV-6 encephal...